Developing therapeutic monoclonal antibodies and ADC's is a key focus of the pharmaceutical industry's R&D. The European Antibody Congress 2012 brought together senior level executives and opinion leaders from around the globe to further their knowledge and engage in discussion on a variety of topics relating to mAbs, ADC's and bispecifics. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Thierry Wurch, Global Director of Antibody Projects, Servier Research Institute, âRevisiting the immune regulatory properties of therapeutic antibodies'.
This presentation focuses on:
Â· Presenting novel cancer killing antibodies, under clinical development which inhibit the immune inhibitory signal from the T cell antigen CTLA4
Â· Exploring that the memory T-cell response may be associated with long term disease control, and may suggest a critical role of the adaptive immune system in the clinical benefit observed with antibody therapies
Â· As antibodies are representing active regulators of the immune system, do specific preclinical models need to be set up to fully address their immune-regulatory properties?
Are you interested in learning more and engaging in discussion on mAbs, ADC's, bispecifics and antibody biosimilars? Do you want to hear the most recent updates on mAbs/ADC's at the clinical stage? Do you want to network with senior executives and opinion leaders from truly international antibody pioneers? Take a look at the European Antibody Congress 2013.